基于深度学习的患者分层,用于临床痴呆试验的预后丰富
Colin Birkenbihl1,2,3, Johann de Jong4, Ilya Yalchyk1,2
1Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Sankt Augustin 53757, Germany.
Brain communications
|December 23, 2024
概括
人工智能在痴呆症患者中发现了明显的阿尔茨海默病进展率. 这种深度学习方法可以优化临床试验,潜在地降低成本并加速治疗认知障碍的药物开发.
科学领域:
- 神经科学是一个神经科学.
- 人工智能的人工智能
- 临床试验 临床试验
背景情况:
- 痴呆症,通常是由于阿尔茨海默病,呈现异质的进展,复杂的临床试验.
- 识别对认知衰退的有效治疗方法是一个重大挑战.
研究的目的:
- 在痴呆症临床试验中应用人工智能来分层患者.
- 为了识别不同的阿尔茨海默病进展轨迹.
- 评估人工智能驱动的丰富对临床试验效率的影响.
主要方法:
- 深度学习被用来根据认知和功能评分对早期痴呆患者的疾病轨迹进行集群.
- 机器学习模型经过训练,可以从基线数据中预测进展子组.
- 模拟了一个假设的临床试验,以评估患者丰富的影响.
主要成果:
- 在一个更大的队列中,确定并验证了两个不同的患者子组",缓慢"和"快速"进展者.
- 一个机器学习分类器实现了0.70 ± 0.01 AUC来预测进展子组.
- 人工智能驱动的丰富可以减少13%以上的样本规模和试验成本.
结论:
- 人工智能驱动的患者分层可以显著提高痴呆症临床试验的成功率.
- 针对认知结果的丰富策略为药物开发提供了更有效的方法.
- 从优化试验中节省的资源可以加速寻找阿尔茨海默病治疗方法.
相关概念视频
Dementia
94
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
94
Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162


